CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial

This trial is testing a new CAR-T cell therapy (CART123) — a type of personalized immune cell treatment — for patients with blood cancers that have come back or stopped responding to other treatments. CAR-T therapy involves modifying your own immune cells to recognize and attack cancer cells. **You may be eligible if...** - You have been diagnosed with AML (acute myeloid leukemia), MDS, BPDCN, or ALL, and your cancer tests positive for a protein called CD123 - Your cancer has relapsed or is refractory (failed to respond) after at least 2 prior treatments, including standard induction chemotherapy or CAR-T targeting CD19 - You have had a relapse after a stem cell transplant - For ALL patients: your cancer stopped responding to CAR-19 therapy or you are not eligible for other standard options **You may NOT be eligible if...** - Your blood cancer does not express the CD123 protein - You have active uncontrolled infections - Your organ function is too poor to handle this type of therapy - You have certain active autoimmune conditions Talk to your doctor to see if this trial is right for you.